Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Boehringer Ingelheim
US Army
Baxter
Moodys
Argus Health
Cantor Fitzgerald
AstraZeneca
Federal Trade Commission

Generated: July 17, 2018

DrugPatentWatch Database Preview

Doripenem - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for doripenem and what is the scope of doripenem freedom to operate?

Doripenem
is the generic ingredient in one branded drug marketed by Shionogi Inc and is included in one NDA. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Doripenem has sixteen patent family members in fourteen countries.

There are five drug master file entries for doripenem. Two suppliers are listed for this compound.
Pharmacology for doripenem
Ingredient-typeCarbapenems
Drug ClassPenem Antibacterial
Synonyms for doripenem
(+)-(4R,5S,6S)-6-((1R)-1-Hydroxyethyl)-4-methyl-7-oxo-3-(((3S,5S)-5-((sulfamoylamino)methyl)-3-pyrrolidinyl)thio)-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
(+)-(4R,5S,6S)-6-[(1R)-1-HYDRO-XYETHYL]-4-METHYL-7-OXO-3-[[(3S,5S)-5-[(SULFAMOYLAMINO)-METHYL]-3-PYRROLIDINYL]THIO]-1-AZABICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID MONOHYDRATE
(4R,5S,6S)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-3-(((3S,5S)-5-((sulfamoylamino)methyl)pyrrolidin-3-yl)thio)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-6-((R)-1-hydroxyethyl)-4-Methyl-7-oxo-3-((3S,5S)-5-((sulfaMoylaMino)Methyl)pyrrolidin-3-ylthio)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-{[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl}-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
016D813
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((aminosulfonyl)amino)methyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, (4R,5S,6S)-
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((aminosulfonyl)amino)methyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-
148016-81-3
364622-82-2
ABP000725
AC1L2JMJ
AJ-47442
AK326124
AKOS015918362
AM84446
AN-7043
AVAACINZEOAHHE-VFZPANTDSA-N
BCP9000623
BCPP000252
BDBM50088382
BHV525JOBH
C-23919
CAS-148016-81-3
CC-27371
CHEBI:135928
CHEMBL1721631
CHEMBL491571
CS-2075
D03895
D03QWT
D5249
DB06211
Doribax
Doribax (TN)
Doripenem (USAN/INN)
Doripenem [USAN:INN]
Doripenem Hydrate/Doribax/S-4661/Finibax/
Doripenem monohydrate
DR002580
DRPM
DSSTox_CID_26678
DSSTox_GSID_46678
DSSTox_RID_81814
DTXSID2046678
Finibax
FT-0081127
FT-0651042
HE111624
HY-B0187
I14-8431
MFCD02092739
MFCD09749887
MolPort-006-069-366
NCGC00167510-01
NCGC00167510-02
RL01870
S 4661
S-4661
SCHEMBL37471
SR-01000872589
SR-01000872589-1
ST2401965
Tox21_112508
Tox21_112508_1
UNII-BHV525JOBH
ZINC3922770

US Patents and Regulatory Information for doripenem

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-001 Oct 12, 2007 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-002 Oct 5, 2010 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for doripenem

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-002 Oct 5, 2010 ➤ Sign Up ➤ Sign Up
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-001 Oct 12, 2007 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for doripenem

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,221,823 Crystal form of pyrrolidylthiocarbapenem derivative ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for doripenem

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB09/006 United Kingdom ➤ Sign Up PRODUCT NAME: DORIPENEM; REGISTERED: UK EU/1/08/467/001 20080725
3 Finland ➤ Sign Up
09/002 Ireland ➤ Sign Up PRODUCT NAME: DORIPENEM.; REGISTRATION NO/DATE: EU/1/08/467/001 20080725
2009 00003 Denmark ➤ Sign Up PRODUCT NAME: DORIPENEM, HERUNDER DORIPENEMMONOHYDRAT; REG. NO/DATE: EU/1/08/467/001 20080725
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Moodys
Accenture
Boehringer Ingelheim
Cipla
US Army
Citi
Cerilliant
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.